<code id='BD057E7EDB'></code><style id='BD057E7EDB'></style>
    • <acronym id='BD057E7EDB'></acronym>
      <center id='BD057E7EDB'><center id='BD057E7EDB'><tfoot id='BD057E7EDB'></tfoot></center><abbr id='BD057E7EDB'><dir id='BD057E7EDB'><tfoot id='BD057E7EDB'></tfoot><noframes id='BD057E7EDB'>

    • <optgroup id='BD057E7EDB'><strike id='BD057E7EDB'><sup id='BD057E7EDB'></sup></strike><code id='BD057E7EDB'></code></optgroup>
        1. <b id='BD057E7EDB'><label id='BD057E7EDB'><select id='BD057E7EDB'><dt id='BD057E7EDB'><span id='BD057E7EDB'></span></dt></select></label></b><u id='BD057E7EDB'></u>
          <i id='BD057E7EDB'><strike id='BD057E7EDB'><tt id='BD057E7EDB'><pre id='BD057E7EDB'></pre></tt></strike></i>

          Home / explore / focus

          focus


          focus

          author:comprehensive    Page View:212
          Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

          In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

          The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks. 

          advertisement

          “Oh, crap,” Secrist said to herself.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In